March 2025 Life Sciences Update

The Pipeline of Active Clinical Trials Remains Robust Globally

05

CONTENTS

All Currently Active Global Clinical Trials

Number of Global Active Clinical Trials By Start Year and Phase

• Reaching a clinical trial stage continues to be critical for companies seeking funding. Advancing from early Phase 1 to Phase 2 demonstrates growth and a potential path to FDA approval, strengthening investor confidence in a company’s path to clinical trial success. • Currently, Phase 2 trails account for 42% of all clinical trials in the global pipeline, and 18%, have advanced to Phase 3, where FDA approval is possible. • Most active clinical trials were initiated in 2023, with 39% now in Phase 2. Although fewer clinical trials started in 2024, a significant portion have already advanced to Phase 2 (37%) and Phase 3 (15%). • Clinical trials in Phases 1-3 generally require human participants in the studies. As more companies advance to a clinical trials stage, their need for space increases.

Early Phase 1

Phase 1

Phase 2 Phase 3 Phase 4

Early Phase 1 4%

3,500

3,000

Phase 4 10%

2,500

Phase 1 26%

Phase 3 18%

2,000

1,500

1,000

Phase 2 42%

500

0

2020 2021

2022

2023

2024

Source: Clinicaltrials.gov

26 26

Cushman & Wakefield